Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new treatments ...

Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new ...

The drugmaker will bring on Bristol Myers Squibb exec Daniel Quirk as chief medical officer and head of medical affairs, a ...

Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Biogen (BIIB – Research Report). The associated price target ...

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA ...

Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare ...

Biogen (BIIB) announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, ...